S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:EVGN

Evogene (EVGN) Stock Price, News & Analysis

$0.74
0.00 (0.00%)
(As of 03/28/2024 ET)
Today's Range
$0.73
$0.77
50-Day Range
$0.70
$0.98
52-Week Range
$0.45
$1.44
Volume
58,664 shs
Average Volume
193,536 shs
Market Capitalization
$30.51 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.62

Evogene MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
378.7% Upside
$3.62 Price Target
Short Interest
Healthy
0.17% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.44mentions of Evogene in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.42 out of 5 stars

Medical Sector

755th out of 938 stocks

Agricultural Chemicals Industry

8th out of 10 stocks

EVGN stock logo

About Evogene Stock (NASDAQ:EVGN)

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.

EVGN Stock Price History

EVGN Stock News Headlines

Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
Here's what Wall Street expects from Evogene's earnings report
Evogene Earnings Preview
See More Headlines
Receive EVGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evogene and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/07/2024
Today
3/28/2024
Next Earnings (Estimated)
5/16/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Agricultural chemicals
Sub-Industry
N/A
Current Symbol
NASDAQ:EVGN
Employees
137
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$3.62
High Stock Price Target
$6.00
Low Stock Price Target
$1.85
Potential Upside/Downside
+395.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-23,880,000.00
Net Margins
-423.39%
Pretax Margin
-460.76%

Debt

Sales & Book Value

Annual Sales
$5.64 million
Book Value
$0.70 per share

Miscellaneous

Free Float
38,166,000
Market Cap
$30.10 million
Optionable
Optionable
Beta
1.50
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. Ofer Haviv CPA (Age 58)
    CEO & President
    Comp: $437k
  • Mr. Mark Kapel (Age 47)
    Chief Technology Officer
    Comp: $276k
  • Mr. Sassi Masliah (Age 45)
    Vice President of Corporate Development
    Comp: $245k
  • Dr. Nir Arbel (Age 44)
    Chief Product Officer
    Comp: $247k
  • Dr. Brian Ember (Age 48)
    Chief Executive Officer of AgPlenus Ltd
    Comp: $294k
  • Mr. Yaron Eldad (Age 59)
    Chief Financial Officer
  • Rachel Pomerantz Gerber
    Head of Investor Relations
  • Ms. Liat Foigel Wejgman
    Vice President of Human Resources
  • Mr. Eyal Ronen
    Executive Vice President of Business Development
  • Dr. Elran Hillel Haber M.B.A. (Age 44)
    Ph.D., Chief Executive Officer of Biomica Ltd
    Comp: $287k

EVGN Stock Analysis - Frequently Asked Questions

Should I buy or sell Evogene stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Evogene in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" EVGN shares.
View EVGN analyst ratings
or view top-rated stocks.

What is Evogene's stock price target for 2024?

3 Wall Street research analysts have issued 12 month target prices for Evogene's shares. Their EVGN share price targets range from $1.85 to $6.00. On average, they anticipate the company's share price to reach $3.62 in the next year. This suggests a possible upside of 378.7% from the stock's current price.
View analysts price targets for EVGN
or view top-rated stocks among Wall Street analysts.

How have EVGN shares performed in 2024?

Evogene's stock was trading at $0.84 at the beginning of the year. Since then, EVGN stock has decreased by 10.1% and is now trading at $0.7555.
View the best growth stocks for 2024 here
.

Are investors shorting Evogene?

Evogene saw a decrease in short interest in the month of March. As of March 15th, there was short interest totaling 71,600 shares, a decrease of 47.5% from the February 29th total of 136,300 shares. Based on an average daily volume of 195,400 shares, the days-to-cover ratio is currently 0.4 days.
View Evogene's Short Interest
.

When is Evogene's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 16th 2024.
View our EVGN earnings forecast
.

How were Evogene's earnings last quarter?

Evogene Ltd. (NASDAQ:EVGN) announced its quarterly earnings data on Thursday, March, 7th. The biotechnology company reported ($0.13) EPS for the quarter, topping analysts' consensus estimates of ($0.14) by $0.01. The biotechnology company had revenue of $0.58 million for the quarter, compared to the consensus estimate of $1.73 million. Evogene had a negative trailing twelve-month return on equity of 76.93% and a negative net margin of 423.39%. During the same quarter in the previous year, the company posted ($0.07) earnings per share.

What other stocks do shareholders of Evogene own?
Who are Evogene's major shareholders?

Evogene's stock is owned by many different institutional and retail investors. Top institutional shareholders include Simplex Trading LLC (0.00%), Citadel Advisors LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of Evogene?

Shares of EVGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:EVGN) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners